<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452267</url>
  </required_header>
  <id_info>
    <org_study_id>MetPioMuscle</org_study_id>
    <nct_id>NCT03452267</nct_id>
  </id_info>
  <brief_title>Insulin Signaling in Skeletal Muscle</brief_title>
  <official_title>Effect of Metformin and Pioglitazone on Insulin Signaling in Skeletal Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The insulin sensitizing effects of metformin and pioglitazone in the skeletal muscle remain
      unknown. Our group aims to analyze molecular changes within the skeletal muscle of
      pre-diabetic patients through the use of a clinical trial in humans.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteomic</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in global protein abundance levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proteomic 2</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in global protein phosphorylation levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epigenomic</measure>
    <time_frame>3 months</time_frame>
    <description>Change in global DNA percent methylation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral, 850 mg twice daily</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>oral, 45 mg daily</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-diabetes as defined by an oral glucose tolerance test 2-hour level between 140 and
             200 mg/dL

        General Inclusion Criteria:

          -  Able to communicate meaningfully with the investigator and legally competent to
             provide informed written consent.

          -  Female subjects must be non-lactating, have a negative pregnancy test, and be on
             acceptable birth control.

        Exclusion Criteria:

          -  Oral glucose tolerance test &lt;140 or &gt;200mg/dL

          -  Treated with any of the following medications:

               -  Systemic glucocorticoids (more than 2 weeks), antineoplastic agents, transplant
                  medications, fibrates, anti-retroviral medications, or thiazolidinediones within
                  6 months prior to screening

               -  Start or change of hormonal replacement therapy within 3 months prior to
                  screening

               -  Short-acting insulin (more than15 units per day) in DMT2 subjects, indicating
                  severe insulin deficiency within 6 months prior to screening

          -  History or presence of any of the following conditions:

               -  Clinically significant heart disease (New York Heart Classification greater than
                  grade II; more than non-specific ST-T wave changes on the EKG)

               -  Peripheral vascular disease (history of claudication)

               -  Clinically significant pulmonary disease.

               -  Current uncontrolled hypertension (systolic BP&gt;160 mmHg, diastolic BP&gt;100 mmHg)

               -  History or presence of malignancy other than basal cell or squamous cell skin
                  cancer

               -  Autonomic neuropathy

               -  Clinically significant hematologic disease

          -  Any of the following abnormal laboratory values:

               -  Hematocrit &lt; 35 vol%

               -  Serum creatinine &gt; 1.6 mg/dl

               -  AST, ALT or Alkaline phosphatase &gt; 2.5 times the upper limit of normal

               -  PT, PTT outside the normal reference range

               -  TSH outside the normal reference range

               -  Triglycerides &gt; 400 mg/dl

               -  Platelet count &lt; 50,000

          -  Current or history of drug abuse or alcohol abuse

          -  Blood donation within 2 months prior to screening

          -  Engage in exercise with moderate to hard intensity for greater than 1 hour per day for
             5 or more days per week.

          -  Diagnosed with Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>Kyle Burghardt</investigator_full_name>
    <investigator_title>Assistant Professor of Pharmacy Practice</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

